Gap Inc vs TG Therapeutics Inc — how do they compare? Gap Inc trades at $20.81 (market cap $7.30B), while TG Therapeutics Inc trades at $55.89 (market cap $8.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Gap Inc pays a 3.45% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GAP | TGTX | |
|---|---|---|
Market Cap | $7.30B | $8.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $59.06 |
52-Week Low | $18.35 | $26.39 |
Enterprise Value | $10.38B | $8.88B |
Dividend Yield | 3.45% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $56.20, up 2.39% on the day, with a bullish technical signal and strong analyst consensus (84.6% buy ratings). The stock's momentum is supported by robust revenue growth, with 2025 revenue reaching $616.29M and net income of $447.18M, yielding impressive profitability margins (Gross Margin: 83.05%, ROE: 112.6%). Recent positive clinical updates for Briumvi in multiple sclerosis and schizophrenia trials have fueled investor optimism and media coverage.
The outlook remains positive due to Briumvi's commercial expansion and pipeline progress, though risks include earnings volatility (two recent misses), high valuation multiples (EV/EBITDA: 59.1), and clinical trial dependencies. The current price sits above the consensus price target of $48.50, suggesting near-term valuation concerns may limit upside unless operational execution continues to exceed expectations.
Trailing returns across standard periods
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →